Please see thread here https://www.s4me.info/threads/reverse-long-covid-19-with-baricitinib-study-reverse-lc.36979/ Is the Baricitinib trial worth doing? Is it worth spending $30 million USD on the trial?
This must be the pilot scale study? Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813065/
One two person LC case report I found on Twitter. Most evidence seems to be about acute COVID. https://www.s4me.info/threads/rever...ricitinib-study-reverse-lc.36979/#post-536631
No this is the trial for acute Covid-19 by Wes Ely. According to Ely, Baricitinib is one of the most effective drugs for severe acute Covid and that surely played some role in them hoping it would work in LC. He has presented his thoughts in some interviews/conferences but I can't claim to have understood the narrative to trial Baricitinib in LC.
https://twitter.com/user/status/1521105261699780609 REVERSE-LC was originally a pilot study and they converted it: https://twitter.com/user/status/1733602591903301692
OK I’m still confused. Did he have some promising data from his pilot study? FWIW, I voted for conducting a Baricitinib trial at a lower funding level. A $30 million dollar trial would be the largest drug trial for LC +MECFS maybe by an order of magnitude. Maybe the Fluge phase 3 ritux would be the largest before this?
There's a Baricitinib thread here. From what I've understood there was no pilot study. The initial plan was to do a smaller study/pilot study but they eventually got a sufficiently large grant and decided to directly go for a big study.
